GlassScriptPhysician profile
Marie Eddins
NPI 1235882481
$1,109.91
in general payments reported to CMS, 2019-2025
16 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Obstetrics & Gynecology (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Obstetrics & Gynecology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $160 · 2023: $374 · 2024: $456 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $885 · Education: $64.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $884.79 |
| Education | $64.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $313.33 | 2023-2024 | Veozah, Myrbetriq |
| Axonics, INC. | $135.56 | 2024 | Axonics, Bulkamid |
| Bayer Healthcare Pharmaceuticals INC. | $111.81 | 2022-2025 | |
| Mayne Pharma Commercial LLC | $100.80 | 2022-2023 | |
| Sage Therapeutics, LLC | $100.19 | 2024-2025 | Zurzuvae |
| Abbvie INC. | $46.04 | 2022-2023 | |
| Exeltis, USA INC. | $45.55 | 2023-2024 | Slynd |
| Organon LLC | $43.24 | 2024-2025 | Nexplanon |
| Therapeuticsmd, INC. | $39.60 | 2022 | |
| Merck Sharp & Dohme LLC | $38.24 | 2023-2024 | Gardasil 9, Gardasil |
| Coopersurgical, INC. | $29.87 | 2022-2024 | Paragard T 380a |
| Ethicon US, LLC | $26.23 | 2024 | Stratafix |
| Innovation Technologies INC | $25.65 | 2024 | Irrisept |
| Hologic Sales and Service, LLC | $18.35 | 2025 | Thinprep 2000 Processor, Aptima |
| Sumitomo Pharma America, INC. | $17.83 | 2023 | Myfembree |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $17.62 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marie Eddins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.